Chemo Therapy - malecare.org

Rapid PSA Decline After Docetaxel Chemotherapy is Associated with Improved Survival in Hormone Refractory Prostate Cancer

A chart review performed at the Department of Internal Medicine, University of Alberta, Edmonton, AB. concluded that the a quick rate of initial PSA decline in men with hormone refractory prostate cancer receiving docetaxel chemotherapy (chemo) predicts an increased overall survival (OS). Studies have demonstrated that docetaxel chemotherapy does prolong survival in metastatic hormone-refractory prostate [...]

By Malecare|2009-11-11T12:29:08-05:00November 11th, 2009|Advanced Prostate Cancer, Chemo Therapy, Drugs & Treatments, End-Of-Life, Uncategorized, Understanding APC|0 Comments

On the Horizon – Phase III Trial of MDV3100 in Advanced Prostate Cancer Begins

Medivation, Inc. (MDVN) has formally begun its phase III trial of the investigational drug MDV3100 with men who have advanced prostate cancer. The clinical trial known as AFFIRM will evaluate the novel androgen receptor antagonist, MDV3100, in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy. AFFIRM is a randomized, placebo-controlled, double-blind, [...]

By Malecare|2021-02-17T10:55:32-05:00October 30th, 2009|Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Hormone Therapy, MDV3100, On The Horizon, Uncategorized|3 Comments

Scott Goodwin Checks In

Scott Goodwin who periodically has been writing about his journey taking chemotherapy has given us a very moving update. Sadly, Scott is not doing well physically, but he is continuing his valiant fight against this insipid disease. - JTN I thought I would send a much overdue update on my progress with chemo, etc. I [...]

By Malecare|2017-10-19T10:54:25-04:00October 27th, 2009|Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Hormone Therapy, Personal Experiences, Scott Godwin - Chemotherapy, Uncategorized, Understanding APC|12 Comments

THALIDOMIDE FOR THE TREATMENT OF BIOCHEMICALLY RECURRENT PROSTATE CANCER (PSA Recurrence)

According to a randomized study run and reported by William D.Figg, PharmD, head of the Molecular Pharmacology Section of the Centerfor Cancer Research at the National Cancer Institute, in Bethesda, MD. And published online January 23, 2009 in the Journal of Urology (Vol. 181, pp.1104-13), Thalidomide may be effective for the treatment of men who [...]

By Malecare|2017-10-19T10:54:28-04:00October 22nd, 2009|Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, thalidomide, Uncategorized|0 Comments

On The Horizon- FDA Grants Fast Track Designation for OGX-011 in The Treatment of Prostate Cancer

OncoGenex Pharmaceuticals, Inc. (OGXI) announced that it's experimental product, OGX-011, also known as custirsen sodium, received fast track designation from the U.S. Food & Drug Administration (FDA) for the treatment of progressive metastatic prostate cancer in combination with first-line docetaxel treatment (chemotherapy). OGXI had previously received this same designation for second-line docetaxel treatment with OGX-011 [...]

By Malecare|2017-10-19T10:54:28-04:00October 12th, 2009|Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, FDA, Metastases, On The Horizon, Uncategorized|0 Comments